Emcure Pharmaceuticals, based in New Delhi, has announced a 55% price reduction for its weight management drug, Poviztra, effective from April 3, 2026. The starting dose of the semaglutide injection will now be priced at ₹3,999 (approximately $48 USD) per month, down from ₹8,790. This price cut aims to enhance patient access to the drug, which is crucial as obesity rates continue to rise in India, affecting nearly 254 million individuals. Emcure, as the exclusive distributor of Poviztra, seeks to make this proven therapy more accessible amidst growing public health concerns related to weight management. The average price reduction across all doses is 47%, with Poviztra available in five strengths ranging from 0.25 mg to 2.4 mg. Satish Mehta, CEO of Emcure, highlighted the company's commitment to improving health outcomes and addressing the obesity epidemic in India through this initiative.